Seeking Alpha

tommy richardson's  Instablog

tommy richardson
Send Message
I've been trading and investing for over 30 years and have found that a little research with long holding periods has made more money than day trading. I am a strong advocate of using the immense power of the internet to research anything you can imagine.
  • Why Catalyst Is Ready To Fly Again 8 comments
    Nov 11, 2013 10:15 AM | about stocks: ACAD, AEGR, BMRN, PFE, CPRX

    For the past six months shareholders of Catalyst Pharmaceutical Partners' (NASDAQ:CPRX) have been unusually big winners with shares soaring almost 1,000% from $.37 to a new high of $3.65. Shares have been rising dramatically because Catalyst has successfully positioned into the exciting space of orphan drugs and is even being compared to high flying orphan drug developers like Aegerion Pharmaceuticals (NASDAQ:AEGR) and Acadia Pharmaceuticals (NASDAQ:ACAD). See, "Strong Comps Indicate Catalyst Pharmaceutical Partners Outstanding Value Proposition."

    On October 18th, Catalyst's rocket ride came to a temporary halt when a negative article published by "The Street" sent shares tumbling to $1.40. The article unfairly blasted Catalyst for being greedy, and alleged that their drug Firdapse was the same as, and no better than Jacobus Pharmaceuticals' version of Firdapse called 3,4 Dap. The article praised Jacobus as a Robin Hood because they were giving away their version of Catalysts' Firdapse for free but what the author failed to mention was that fact that Jacobus cannot legally charge for their drug. Since 3,4 Dap is not approved by the FDA it must be given away for free. In fact, there were several things not mentioned that tended to mislead the reader.

    The article had a serious impact on Catalyst shares, but it also backfired on Jacobus by bringing to light the fact that they are manufacturing their drugs in an abandoned Nuclear Reactor Test Site and that they have been repeatedly cited by the FDA for #483 manufacturing safety violations. A closer look into the two companies reveals that Jacobus is only in a Phase II trial for 3, 4 Dap while Catalyst's Firdapse is in a final Phase III trial. It has also been revealed that 3, 4 Dap is not the same as Firdapse as it is Free Base and Firdapse is Phosphate salt. Firdapse has a stable shelf life and 3,4 Dap does not. The dose for 3,4 Dap is not known and the dose for Firdapse is known. And most significant, Firdapse is already approved and selling in Europe.

    Seeing an opportunity to take advantage of the steep decline in Catalyst's share price, a number of law firms publicly announced they filed class action lawsuits and seek to find a lead plaintiff to step forward that feels they were damaged by Catalyst. These frivolous lawsuits are usually wasteful but if anyone should be sued for damages, the author admits responsibility in his recent blog "6 Charts Explain An Ugly October for Biotech Stocks" where he brags, "I probably had something to do with the Catalyst sell off." It's unlikely this matter will ever get to court, but if it does, it would not be surprising to see any and all claims against Catalyst dismissed. There have been comments on Catalyst's message board on Yahoo about unhappy shareholders commencing a lawsuit against the author.

    Now that investors and traders have learned that Jacobus is not the savior nor the threat they were portrayed to be, the heavy selling has abated and trading volume has dried up to only a small fraction of the normal daily volume of 2.7 million shares. Four days ago, Jacobus was exposed in a surprising blog showing official government documents called 483's demonstrating large numbers of FDA violations by Jacobus. The expose' of Jacobus is spreading fast as another article appeared in Pharmalot today titled, "Calalyst Pharma Fights Greed Charges Over An Orphan Drug." Since Jacobus has had orphan designation of 3,4 Dap for over 20 years and still has no approval, one has to ask, "just how serious can they be?"

    Now that both sides of the story are out and on the table, the stock plunge is over and traders are regrouping and rethinking as shares are putting in a bottom. Based on facts and not speculation, it's easy to understand why Catalyst shares have been soaring and why they will continue hitting new highs as soon as traders realize they have been mislead by a single article. Consider that insiders are buying and not selling. Consider that only recently the FDA designated Catalyst's orphan drug Firdapse a "Breakthrough Therapy" for the treatment of LEMS disease, Lambert Eaton Myasthenic Syndrome. Consider that Catalyst raised $15 million at $1.70 per share in September and is adequately financed to complete the current phase III Firdapse trial. Consider that only a few weeks ago, based on positive data, an independent Data Monitoring Committee recommended continuation of the phase III pivotal trial for Firdapse. And to repeat, Firdpase is already approved and commercially available in Europe and therefore has a very high probability of being approved in the United States where Catalyst owns the North American rights.

    If that's not enough, even more reasons Catalyst is getting ready to fly again are; top line results from the Firdapse trial are expected as soon in H1 2014; results from a small study of CPP109 (CPP115) on Tourette's Syndrome are expected in the coming months; CPP 115 is a potential blockbuster drug for several indications including epilepsy, refractory epilepsy, infantile spasms, Tourette's Syndrome and movement disorders and was designed by the well-known Dr. Richard Silverman who also created the blockbusters Lyrica and Neurontin for Pfizer (NYSE:PFE). If results are positive, this could send shares flying to new highs. And finally, consider the persistent buyout rumors that BioMarin (NASDAQ:BMRN) who has already purchased 17% of Catalyst may make bid for the balance before the price gets too high. BioMarin has a reputation of buying companies like Catalyst when they are cheap and that can add valuable drugs to their pipeline like Firdapse and CPP115.

    Like every small cap pharma company, Catalyst Pharmaceutical Partners has risk of failed clinical trials, risk of inability to raise adequate capital to remain an ongoing concern, risk that the market may not accept their drugs, risk of inadequate pricing, and risk that a major event in the stock market may have an adverse impact on shares.

    Unlike many other small-cap pharma companies, Catalyst is close to multiple milestone achievements and is poised to resume flying to new highs soon. The recent selloff offers a second chance for those who missed the boat last summer and it won't take long for traders and investors to realize that this is the same high growth company that it was before "The Street" article appeared. The lawsuits are frivolous and without merit, and nothing has changed except the company continues to get closer to its milestone achievements.

    I believe the current selloff represents a timely and excellent buying opportunity.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

    Themes: long-ideas Stocks: ACAD, AEGR, BMRN, PFE, CPRX
Back To tommy richardson's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (8)
Track new comments
  • mokofeyz
    , contributor
    Comments (33) | Send Message
    Thanks for the blog. There has been much anxiety in the retail investing community with the stock drifting down. Hopefully, this article will alleviate most of those who are worried that they will lose their hard-earned money, especially Mr. Duckboy.
    11 Nov 2013, 01:04 PM Reply Like
  • tommy richardson
    , contributor
    Comment (1) | Send Message
    Author’s reply » We can all help spread the truth by circulating this article to people who are in the dark but need to know.
    11 Nov 2013, 07:37 PM Reply Like
  • BioInvestor2013
    , contributor
    Comments (20) | Send Message
    thanks for this article !! CATALYST PHARMACEUTICALS PARTNERS is clearly a STRONG BUY at this low Level !! Cprx is a big rival for $ACAD & $QCOR !! i expect more than 100% gain from now in the next 6 weeks ! GLTA
    11 Nov 2013, 02:49 PM Reply Like
  • audioamigo
    , contributor
    Comment (1) | Send Message


    Thank you so much for this article! You have articulated my thoughts exactly! (But I would have used more profanity. :-)


    I treasure my shares in this fine company and look forward to watching them prevail and prosper. I also hope a couple of people at TheStreet are exposed for their brand of "journalism".




    E. Gordon Bishop
    11 Nov 2013, 07:37 PM Reply Like
  • SMU1979
    , contributor
    Comments (4) | Send Message
    Additionally, if the people on this site knew anything about LEMS (including Catalyst), they would know that the proper dose differs for each LEMS patient, so the claim that the dose for Firdapse is known is spurious.
    11 Nov 2013, 08:58 PM Reply Like
  • SMU1979
    , contributor
    Comments (4) | Send Message
    DAP - the medicine that Catalyst is trying to receive FDA approval for has been used to treat LEMS successfully for over 20 years. I personally have used it for over 12 years - receiving it totally free of charge from Jacobus Pharmaceutical. Biomarin, the company which sold it to Catalyst in the US, had its stock downgraded because it didn't make as much on Firdapse as it had hoped after purchasing it for over 22 million dollars from Huxley Pharmaceutical. If Firdapse is at all different from the 3, 4 DAP produced by Jacobus Pharmaceutical it's from added stabilization. In 12 years of taking packing my medication for 3 weeks at a time and carrying it in all kinds of weather and temperatures, it has never failed me.
    11 Nov 2013, 08:59 PM Reply Like
  • soelinn
    , contributor
    Comments (4) | Send Message
    Only 200 people able to access 3,4 DAP. You mean the rest 2800 people need to sacrifice for you to get the drug with free of charge?
    13 Nov 2013, 06:48 PM Reply Like
  • Ares77manoe
    , contributor
    Comments (8) | Send Message
    Should put this on yahoo.Great article.
    12 Nov 2013, 06:53 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.